ArticleDrugs in R&D2016
Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.
Article in Drugs in R&D, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis.BMJ global health · 2023Pooled it
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Microneedle-Assisted Delivery of Biologics: From Large Molecules to Cancer Vaccines.AAPS PharmSciTech · 2026Review
- Microneedles: Selected Applications for Pediatrics.Children (Basel, Switzerland) · 2026Review
- Dissolvable Microneedles with Their Design, Materials, and Limitations in Translation: a Technical Review.AAPS PharmSciTech · 2025Review
- Evolving transdermal therapeutics: a review on self-dissolving polymeric microneedlesRSC advances · 2025Review
- Review
- Article
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.Drug delivery and translational research · 2025Article
- Respiratory syncytial virus vaccines for toddlers and school-aged children: a pressing necessity for global health.Frontiers in pediatrics · 2025Article
- Diagnosing cystic fibrosis in low- and middle-income countries: challenges and strategies.Orphanet journal of rare diseases · 2024Review
- Article
- Article
- Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.BMJ global health · 2023Article
- Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Human vaccines & immunotherapeutics · 2022Review
- A Review of 3D-Printing of Microneedles.Pharmaceutics · 2022Review
- Article
- Article
- Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.PLOS global public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrently available measles vaccines are administered by subcutaneous injections and require reconstitution with a diluent and a cold chain, which is resource intensive and challenging to maintain. To overcome these challenges and potentially increase vaccination coverage, microneedle patches are being developed to deliver the measles vaccine. This study compares the cost-effectiveness of using microneedle patches with traditional vaccine delivery by syringe-and-needle (subcutaneous vaccination) in children's measles vaccination programs.
methodsWe built a simple spreadsheet model to compute the vaccination costs for using microneedle patch and syringe-and-needle technologies. We assumed that microneedle vaccines will be, compared with current vaccines, more heat stable and require less expensive cool chains when used in the field. We used historical data on the incidence of measles among communities with low measles vaccination rates.
resultsThe cost of microneedle vaccination was estimated at US$0.95 (range US$0.71-US$1.18) for the first dose, compared with US$1.65 (range US$1.24-US$2.06) for the first dose delivered by subcutaneous vaccination. At 95 % vaccination coverage, microneedle patch vaccination was estimated to cost US$1.66 per measles case averted (range US$1.24-US$2.07) compared with an estimated cost of US$2.64 per case averted (range US$1.98-US$3.30) using subcutaneous vaccination.
conclusionsUse of microneedle patches may reduce costs; however, the cost-effectiveness of patches would depend on the vaccine recipients' acceptability and vaccine effectiveness of the patches relative to the existing conventional vaccine-delivery method. This study emphasizes the need to continue research and development of this vaccine-delivery method that could boost measles elimination efforts through improved access to vaccines and increased vaccination coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.